The aim of this benefit assessment was to compare the effects of long-term treatment with rapid-acting insulin analogues (RAIs) vs. short-acting regular human insulin (RHI) (and also compare the effects of different RAIs with each other) with regard to patient-relevant outcomes in patients with type 2 diabetes. In this text, the term “rapid-acting insulin analogues” (or “RAIs”) refers to all currently approved and available preparations of this type in Germany: insulin aspart, insulin glulisine, and insulin lispro. The term “short-acting insulin” refers to RHI; “longer-acting insulin” refers to intermediate-acting (e.g. Neutral Protamin Hagedorn [NPH]) and/or long-acting insulin (e.g. ultralente). This benefit assessment was conducted on the basis of the comparison and weighing of desired and undesired effects of the respective drugs (weighing of benefits and harms).
这项获益评估的目的是比较长效速效胰岛素类似物（RAIs）与短效常规人胰岛素（RHI）长期治疗的效果（以及相互比较不同RAIs的效果），涉及2型糖尿病患者与患者相关的结局。在本文中，术语“速效胰岛素类似物”（或“RAIs”）指德国目前所有已批准和可用的此类制剂：门冬胰岛素、谷赖胰岛素和赖脯胰岛素。术语“短效胰岛素”指RHI；“长效胰岛素”指中效胰岛素（如中性鱼精蛋白锌胰岛素[NPH]）和/或长效胰岛素（如特慢胰岛素锌悬液）。这项获益评估是在比较和权衡各药物的预期和非预期效果（权衡获益与危害）的基础上进行的。
